Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I kind of like this one for this time also.
ADSX look at different Aroon
ADSX looking like a bottom.
Thx chip, I appreciate your thoughts. You're right need to learn to trade the correct way.
Wow #17.
And just a few more.
Some more pennies.
LYNX Aroon cross
Nice. Sold AMHI @ .159 from .073. and won't you believe it it is now .174. LOL
More pennies.
Up 117% had since Dec. 7. up higher after I sold now to .164 AMHI may continue, would rebuy on pull back.
All out AMHI @.159
They are buying @ .159 but not taking my shares.
Sold 3rd AMHI in .073 out .159 I'm the hi ask at .159, hi of day .165
Looks like some misplaced thier . :)
Here are some of the peny stocks.
CMTN Cooper Mountain was one of the leaders in high-speed broadband networking as telephone companies -- and later cable providers -- began installing high-speed lines for customers. At one point, Cooper Mountain shares hit an all-time high of $1,236.87 per share on July 17, 2000.
SVA bird flu vac.
"Time has come":)
Bet you it goes up.LOL
Was that an IPO? Iwas looking at that tonight.
Can't find when should be soon.
Agreed. What you think of CTXS
You missed the CALL by 2 months. J/K
Yes it has been performing well. I've be watching it instead of buying it from the high 6 low 7. LOL
Yes, we've just got to find them before the fact.
BEV look at aroon cross.
JDSU possible turn here.
Let's find some of these that are going to pop in 4 to 5 days.
Got a little cash. :)
Started watching this awhile ago cause daughter has MS.
Probably should pick up a few shares.
Topic: FINANCIAL VALUE OF TYSABRI® (formerly known as Antegren®) TO ELAN CORPORATION.
As many of you may be aware, on November 23, 2004 the FDA approved Tysabri® for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is important to note that Tysabri® is not in direct competition with BioMS, since MBP8298 targets secondary progressive multiple sclerosis (SPMS).
Financial Impact to Elan
Following this recent news, which appears to have garnered substantial interest from both the investment and MS community, BioMS management obtained an independent evaluation of the implied financial value of Tysabri® to Elan Corp. It showed that the anticipation by the financial community of FDA approval for Tysabri® resulted in an increase of approximately $7USD billion in market cap for Elan Corp. This corresponds to a rise in stock price from $7USD in February 2004 (when Elan applied for FDA approval for Tysabri®) to $25USD in April 2004 (this value was sustained through November 2004 when Elan received approval of the drug). It is important to note that Elan Corp. only owns 50% of Tysabri® (Biogen Idec owns the remaining 50%).
Tysabri® now provides a recent precedent for the analysis of MS drugs and bodes well for the potential benefit to BioMS Medical if MBP8298 gains approval.
Background
On November 8, 2004, Biogen Idec and Elan Corporation announced that the one-year data from the Phase III Tysabri® AFFIRM trial met the primary endpoint of clinical relapse rate reduction. The international study demonstrated a reduction in the rate of relapses in patients with RRMS by 66% compared to placebo. Subsequent to this announcement, on November 23, 2004, Biogen and Elan announced that the FDA had approved Tysabri® as a treatment for RRMS to reduce the frequency of clinical relapses.
The AFFIRM trial is a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients evaluating the effect of Tysabri® on the progression of disability in multiple sclerosis and the rate of clinical relapse.
Tysabri®, a potential disease modifying treatment, is a humanized therapeutic monoclonal antibody designed to selectively inhibit the migration of immune cells into tissues where they may cause or maintain inflammation. It is administered by intravenous infusion every four weeks.
For your information, listed below are some of the differences between Tysabri® and MBP8298:
TYSABRI® MBP8298
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Tysabri® is a treatment for RRMS; it does not appear that additional studies in SPMS are being pursued at present.
BioMS Medical’s pivotal Phase II/III is in SPMS, for whom the majority of patients have no approved treatment option.
Results from the Phase II trial for Tysabri® indicate that there is a decline in inflammation and relapse rate superior to that of interferons, however, there is no data at this time to show whether it delays disability progression.
The Phase II study of MBP8298 has demonstrated a statistically significant delay of disease progression in an identified responder group that makes up 2/3 or more of MS patients
Long-term safety studies of Tysabri® or comparisons with existing therapies are not available at this time. Full data from the two-year study with the EDSS endpoint will not likely be available until the first half of 2005.
MBP8298 has been used for the treatment of patients at the University of Alberta for a period of 11 years with minimal side effects.
Tysabri® is administered by a 60 minute intravenous infusion every four weeks.
MBP8298 is administered intravenously, once every 6 months - the process takes approximately 5 minutes.
MS.TO
CRDN
ITRO .13x.134
GR's scans
I like the chart, seems QOIL is putting something together.
Take The Money And Run
A guy is walking down the street, sees a beautiful woman with a very
short skirt, approaches her and says, "My god, you're hot!!! I've GOT to
make it with you! I can't help myself, and no matter what, I've GOT to
have you!"
The woman is very shocked and asks him, "What!? HERE? In the middle of
the street!?"
The guy answers, "I've got to have you now! So I'll make you an offer.
I'll drop $500 on the sidewalk and, while you're picking it up, I will
do everything I want. OK?"
The lady seems to be in intense thought. Then she calls her friend. She
tells her friend the story, looking for some advice. The friend says,
"It's no big problem. When he drops the money, you pick up the $500
fast, and he won't even have time to get his fireman out of his pants
before you finish picking it up. Just take the money and run!"
The next day, the friend sees the woman walking like an old woman. The
friend asks, "What happened to you!?"
The woman answers nervously, "That son-of-a-bitch dropped $500 in
quarters!"
QOIL
LOOK ugly at present.
EAG chart no look good at this time.